Blood Coagulation Factors And Fibrin, E.g., Thromboplastin, Etc. Patents (Class 530/381)
-
Publication number: 20120149874Abstract: The present disclosure relates to a method for preparing recombinant glycoproteins with high sialic acid content. More specifically, for UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK) enzyme where point mutation was induced by substituting arginine at position 263 by leucine only or by further substituting arginine at position 266 by glutamine, epimerase activity is constantly maintained, and overexpressed cells thereof experience an increase in intracellular cytidine monophosphate (CMP)-sialic acid content, irrespective of CMP-sialic acid concentration.Type: ApplicationFiled: February 1, 2011Publication date: June 14, 2012Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Jung Hoe Kim, Young Dok Son, Jin Young Hwang, Yeon Tae Jeong
-
Patent number: 8193317Abstract: Methods for producing porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions made by the method of the present invention are useful clinically or as cell-bearing implants.Type: GrantFiled: March 25, 2010Date of Patent: June 5, 2012Assignee: ProChon Biotech Ltd.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Publication number: 20120135931Abstract: The present invention relates to a method of modifying serine protease inhibitors in order to acquire or enhance any one of a variety of desired properties, including extent of inhibition, maintenance of inhibition following cleavage of the serine protease inhibitor by the target serine protease, speed of binding to the serine protease, neutralisation, and binding affinity. The present invention also relates to the products of such modifications and the uses of such products, in particular, their use in therapy.Type: ApplicationFiled: May 5, 2010Publication date: May 31, 2012Applicant: NATURAL ENVIRONMENT RESEARCH COUNCILInventors: R. Manjunatha Kini, Cho Yeow Koh, Kunchithapadam Swaminathan, Kumar Sundramurthy
-
Publication number: 20120121613Abstract: The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate.Type: ApplicationFiled: January 19, 2010Publication date: May 17, 2012Applicant: BAYER HEALTHCARE LLCInventors: Liang Tang, Jun Wang, Baisong Mei, John E. Murphy
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120114630Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: ApplicationFiled: July 9, 2010Publication date: May 10, 2012Applicant: THROMBOGENICS NVInventor: Richard Reinier Zwaal
-
Publication number: 20120107829Abstract: The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention.Type: ApplicationFiled: March 31, 2010Publication date: May 3, 2012Applicant: LEUKOCARE AGInventors: Stefan Margraf, Anja Breuer, Martin Scholz, Jens Altrichter
-
Patent number: 8163496Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.Type: GrantFiled: August 22, 2008Date of Patent: April 24, 2012Assignees: Blood Center Research Foundation, Medical College of Wisconsin, Inc.Inventor: Robert Montgomery
-
Patent number: 8153590Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: September 26, 2008Date of Patent: April 10, 2012Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Patent number: 8143347Abstract: The present invention relates to a proteinaceous construct comprising a blood coagulation factor, e.g., Factor VIII (FVIII), being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol (PEG). Further the present invention relates to methods of preparing PEGylated blood coagulation factor, e.g., FVIII, in the presence of bound antibodies. The invention also relates to methods for prolonging the in vivo-half-life of blood coagulation factor, e.g., FVIII, in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of blood coagulation factor, e.g., FVIII.Type: GrantFiled: October 14, 2009Date of Patent: March 27, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Artur Mitterer, Michael Graninger, Meinhard Hasslacher
-
Publication number: 20120070406Abstract: The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the compositions having low immunogenic potential and/or improved efficacy. The invention achieves these goals by evaluating therapeutic protein preparations for subvisible protein particulates, which can contribute significantly to the overall immunogenic potential of the protein preparation. Further, by maintaining the content of such subvisible protein particulates to below an immunogenic threshold level, the resulting pharmaceutical composition is less likely to result in a loss of tolerance (e.g., upon repeated administration), thereby improving both the safety and efficacy profile of the therapeutic.Type: ApplicationFiled: July 19, 2011Publication date: March 22, 2012Applicants: The Regents of the University of Colorado, A Body Corporate, Barofold, Inc.Inventors: Matthew SEEFELDT, Theodore W. RANDOLPH, Amber Haynes FRADKIN, John CARPENTER
-
Patent number: 8133865Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: GrantFiled: December 27, 2007Date of Patent: March 13, 2012Assignees: Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Patent number: 8119772Abstract: T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma.Type: GrantFiled: September 28, 2007Date of Patent: February 21, 2012Assignees: California Institute of Technology, Regents of the University of CaliforniaInventors: Lili Yang, David Baltimore, Pin Wang, James Economou, Antoni Ribas
-
Publication number: 20120040385Abstract: Disclosed is a technique for obtaining a coagulogen raw material which can irreversibly inactivate the activity of a coagulase while retaining the function of coagulogen in an LAL reagent, a LAL reagent contaminated by an organism-derived biologically active substance or the like, and which can be used in a reagent. An LAL reagent is heated at a predetermined temperature for a predetermined period of time to deactivate only the activity of an enzyme contained in the LAL reagent irreversibly, wherein such an activity inherent in coagulogen that coagulogen can be hydrolyzed with the activated coagulase and converted to coagulin to induce gelatinization or an agglutination reaction is retained.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventor: Katsumi Yabusaki
-
Publication number: 20120040905Abstract: An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are immobilized.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Michel Nogre
-
Patent number: 8114840Abstract: The invention concerns the use of antithrombin III with a modified conformation which is referred to as activated antithrombin III (IDAAT=immune defense activated antithrombin) as a medicament.Type: GrantFiled: June 11, 2008Date of Patent: February 14, 2012Assignee: Hamburger Stiftung zur Forderung Von Wissenschaft und KulturInventors: Beate Kehrel, Martin Brodde
-
Publication number: 20120035344Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: July 29, 2011Publication date: February 9, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
-
Publication number: 20120035110Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: ApplicationFiled: July 8, 2011Publication date: February 9, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: LEOPOLD GRILLBERGER, MANFRED REITER, WOLFGANG MUNDT
-
Patent number: 8084580Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterized in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.Type: GrantFiled: March 21, 2007Date of Patent: December 27, 2011Assignee: Grifols, S.A.Inventors: Juan Ignacio Jorquera Nieto, Nuria Hosta Mateu, Olga Santaeularia Lozano
-
Patent number: 8084591Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: December 27, 2011Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20110305770Abstract: The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker.Type: ApplicationFiled: November 17, 2009Publication date: December 15, 2011Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong Zhao, Weili Yan, Lianjun Shi, Dechun Wu
-
Patent number: 8071725Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8071726Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8067543Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: November 29, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20110287518Abstract: The invention relates to the purification of different gamma carboxylated forms of a polypeptide using ion exchange chromatography. In particular, the invention provides a method for purifying a polypeptide having a desired content of gamma-carboxyglutamic acid from a sample comprising mixture of species of said polypeptide having different contents of gamma-carboxyglutamic acid, said method comprising the steps of: (a) loading said sample onto an anion exchange chromatography material; (b) eluting said polypeptide using a solution at a pH of less than pH 9.0 comprising at least one salt selected from ammonium acetate, ammonium chloride and sodium acetate; and (c) selecting a fraction obtained from said elution wherein the polypeptides in the fraction have the desired content of gamma-carboxyglutamic acids.Type: ApplicationFiled: December 1, 2009Publication date: November 24, 2011Applicant: NOVO NORDISK HEALTH CARE A/GInventor: Jais Rose Bjelke
-
Patent number: 8053561Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.Type: GrantFiled: March 8, 2010Date of Patent: November 8, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
-
Publication number: 20110268790Abstract: Compositions and Methods for the treatment of coagulation disorders using Factor V variants are provided. Preferred disorders include hemophilia A and B.Type: ApplicationFiled: November 23, 2009Publication date: November 3, 2011Inventors: Rodney Camire, Mettine H.A. Bos
-
Patent number: 8025803Abstract: An ion-exchange chromatography support for reducing the ADAMTS13 amount present in a plasma-derived solution containing human von Willebrand factor. The support includes a large-pore, vinyl polymer-type resin bearing DEAE groups, and a buffer including trisodium citrate, sodium chloride, calcium chloride, glycine and lysine.Type: GrantFiled: July 7, 2008Date of Patent: September 27, 2011Assignee: LFB BiotechnologiesInventors: Francoise Bridey, Roland Schmitthaeusler
-
Publication number: 20110230645Abstract: The invention provides methods for purifying blood coagulation Factor V from biological fluids.Type: ApplicationFiled: December 15, 2009Publication date: September 22, 2011Inventors: Maartje Verschuur, Evert Heemskerk, Paul Henri Markus, Gerardus Jacobus Van Mierlo
-
Publication number: 20110223151Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.Type: ApplicationFiled: August 6, 2009Publication date: September 15, 2011Applicant: Novo Nordisk Health Care AGInventors: Carsten Behrens, Patrick William Garibay, Soren Østergaard, Henrik Sune Andersen, Johansen Nils Langeland, Peschke Bernd, Bak Sonja
-
Patent number: 8003760Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: August 23, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20110189752Abstract: A complex comprising at least one target protein and at least one binding molecule having a binding affinity for said target protein, wherein said molecule having a binding affinity is covalently or non-covalently bound to at least one water-soluble polymerType: ApplicationFiled: May 6, 2009Publication date: August 4, 2011Inventors: Udo Haberl, Hans -Georg Frank, Andy Poetgens, Marco Emgenbroich, Andreas Rybka, Carola Schräder, Christoph Kannicht
-
Publication number: 20110189182Abstract: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.Type: ApplicationFiled: March 29, 2011Publication date: August 4, 2011Inventors: Hubert METZNER, Thomas Weimer, Stefan Schulte
-
Publication number: 20110190209Abstract: The present invention provides conjugates having a releasable linkage. Methods of making conjugates, and methods for administering conjugates, are also provided.Type: ApplicationFiled: July 31, 2009Publication date: August 4, 2011Applicant: NEKTAR THERAPEUTICSInventors: Sean M. Culbertson, Samuel P. McManus, Mary J. Bossard
-
Publication number: 20110182919Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: November 23, 2010Publication date: July 28, 2011Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James Stattel, Susan C. Low
-
Publication number: 20110183907Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.Type: ApplicationFiled: June 24, 2009Publication date: July 28, 2011Inventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
-
Publication number: 20110182896Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.Type: ApplicationFiled: November 18, 2010Publication date: July 28, 2011Applicant: Syntonix Pharmaceuticals, Inc.Inventors: DANIEL S. RIVERA, Robert T. Peters, Alan J. Bitonti
-
Patent number: 7985839Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: July 26, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 7985846Abstract: A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by chromatographic purification of a vWF-containing plasma fraction on an anion-exchange material which has the anion-exchanging groups on grafted polymeric structures (tentacle materials), collecting a vWF-containing fraction, followed by purification of said fraction using gel permeation to prepare a purified thermally stable vWF-containing preparation; and heating the preparation for inactivating viruses.Type: GrantFiled: January 4, 2007Date of Patent: July 26, 2011Assignee: Octapharma AGInventors: Djuro Josic, Monika Stadler, Gerhard Gruber
-
Patent number: 7982010Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: July 19, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 7977460Abstract: The present invention relates to the use of FIXa and FVIII in the preparation of a composition for the treatment of haemophilia A or haemophilia B in a subject which does not present with anti-FVIII antibodies. The present invention further relates to a composition comprising FIXa and a composition comprising FVIII for simultaneous, simultaneous separate or sequential use in the treatment of haemophilia A or haemophilia B in a subject which does not present with anti-FVIII antibodies.Type: GrantFiled: April 21, 2004Date of Patent: July 12, 2011Assignee: National Institute for Biological Standards and ControlInventor: Trevor Barrowcliffe
-
Publication number: 20110144024Abstract: The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.Type: ApplicationFiled: September 23, 2008Publication date: June 16, 2011Applicant: PAION Deutschland GmbHInventors: Karl-Uwe Petersen, Martin Hauer-Jensen
-
Patent number: 7943739Abstract: A method for precipitating casein from a suspension comprising milk is disclosed. The method includes the following steps: adding a phosphate solution to a suspension; mixing the phosphate solution with the suspension to form a mixture having a phosphate concentration greater or equal to 40 mM; freezing the mixture having a phosphate concentration greater or equal to 40 mM to obtain a frozen mixture; and thawing the frozen mixture to obtain casein-containing aggregates in the mixture, in which the phosphate solution is buffered at a pH value of no less than 4.4.Type: GrantFiled: February 20, 2008Date of Patent: May 17, 2011Assignee: Animal Technology Institute TaiwanInventors: Chon-Ho Yen, Shou-Lun Lee, Mei-Yun Chen, Yin-Shen Lin, Xin-Hui Huang, Chen Hwang Shih, Hsiu-Fen Tai
-
Publication number: 20110077202Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: May 15, 2009Publication date: March 31, 2011Applicant: BAYER HEALTHCARE LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20110046061Abstract: The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.Type: ApplicationFiled: August 2, 2010Publication date: February 24, 2011Applicant: Amunix Operating, Inc.Inventors: Volker Schellenberger, Joshua Silverman, Willem Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Geething, Wayne To
-
Publication number: 20110046060Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.Type: ApplicationFiled: August 2, 2010Publication date: February 24, 2011Applicant: Amunix Operating, Inc.,Inventors: Volker Schellenberger, Joshua Silverman, Willem Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Geething, Wayne To
-
Publication number: 20110040073Abstract: The present invention relates to novel covalent complexes of a Factor VII polypeptide and a Tissue Factor polypeptide, in particular to such complexes which are functionally active and which have an enhanced proteolytic activity towards Factor X compared to the corresponding free Factor VII polypeptide as well as methods for production of these novel complexes.Type: ApplicationFiled: March 30, 2007Publication date: February 17, 2011Applicant: Novo Nordisk HealthCare A/GInventors: Henrik Østergaard, Ole Hvilsted Olsen, Anders Klarskov Petersen, Henning Ralf Stennicke
-
Publication number: 20110028693Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.Type: ApplicationFiled: July 26, 2010Publication date: February 3, 2011Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: JUERGEN SIEKMANN, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20110028397Abstract: The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments. The pharmaceutical compositions according to the invention preferably comprise PAI-2 protein or a derivative thereof retaining uPA-inhibiting capacity, or a tripeptide aldehyde inhibitor, preferably the D-Phe-Pro-Arg-aldehyde (Ald-1). The PAI-2 protein, used according to the invention, is preferably produced through bacterial expression, as a fusion protein.Type: ApplicationFiled: December 1, 2008Publication date: February 3, 2011Inventors: József Tözsér, András Berta, Adrienne Csutak, Gabriella Miklóssy
-
Publication number: 20100322930Abstract: The invention provides fibronectin-based binding molecules and methods for introducing donor CDRs into a fibronectin-based binding scaffold, in particular, Fn3. The fibronectin-based binding molecules of the invention may be further conjugated to another moiety, for example, Fc, anti-FcRn, HSA, anti-HSA, and PEG, for improved half life and stability, particularly in mammalian cells. The invention also provides methods for screening such molecules for binding to a target antigen as well as the manufacture and purification of a candidate binder.Type: ApplicationFiled: December 22, 2008Publication date: December 23, 2010Inventors: Frank Kolbinger, Karen Jane Vincent, Barbara Brannetti, Stefan Ewert